Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Intelgenx Corp. has 3 pending office actions currently active within the Biotechnology & Pharmaceuticals technology area. These applications are spread across 3 distinct examiners and 3 distinct art units. This distribution suggests that each matter is being handled by a different individual, preventing any consolidation of prosecution strategy under a single examiner.
SAEED, ALI S is identified as the busiest examiner, though this individual only manages 1 pending office action. This action is part of the 3 total pending office actions for the company. Because the 3 active matters are located in 3 different art units, the applicant faces a diverse range of examination environments within the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, ALI S | 1 | 31.3% | +35.8% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275610 | HIGH LOADING ORAL FILM FORMULATION | ATKINSON, JOSHUA ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18208177 | NOVEL DISINTEGRATION ORAL FILM FORMULATION WITH A CONTROLLED OR SUSTAINED ACTIVE RELEASE | KWON, JOHN SEUNGJAI | 3d overdue |
| 18276918 | NOVEL TRYPTAMINE ORAL FILM FORMULATION | SAEED, ALI S | — |
| 18275610 | HIGH LOADING ORAL FILM FORMULATION | ATKINSON, JOSHUA ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1612 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276918 | NOVEL TRYPTAMINE ORAL FILM FORMULATION | SAEED, ALI S | 1616 | §103§112DP | Final Rejection | — | Pending | Aug 11, 2023 |
| 18275610 | HIGH LOADING ORAL FILM FORMULATION | ATKINSON, JOSHUA ALEXANDER | 1612 | §103§112Other | Final Rejection | — | Pending | Aug 03, 2023 |
| 18208177 | NOVEL DISINTEGRATION ORAL FILM FORMULATION WITH A CONTROLLED OR SUSTAINED ACTIVE RELEASE | KWON, JOHN SEUNGJAI | 1615 | §103 | Final Rejection | 3d overdue | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial